PFS: Benefit consistent in major histologies
Nintedanib +
docetaxel
Placebo +
docetaxel
Median, mo
4.0
2.8
HR (95% CI)
0.77
(0.62–0.96)
p value
0.0193
Adenocarcinoma
Squamous-cell carcinoma
Nintedanib +
docetaxel
Placebo +
docetaxel
Median, mo
2.9
2.6
HR (95% CI)
0.77
(0.62–0.96)
p value
0.02
100
80
60
40
20
0
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Time (months)
Probability of PFS (%)
Number at risk
277
285
150
129
86
70
32
28
13
12
1
1
1
1
0
0
Nintedanib
Placebo
100
80
60
40
20
0
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Time (months)
Probability of PFS (%)
Number at risk
240
247
122
101
59
36
22
13
5
8
3
1
2
0
1
0
Nintedanib
Placebo
0
0
PFS = progression-free survival; mo = months; HR = hazard ratio; CI = confidence interval.
Reck M,
et al
.
Lancet Oncol
. 2014;15:143-55.
